Bio-Rad Laboratories, Inc.
BIO
$279.03
-$5.65-1.99%
NYSE
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 693.20M | 653.00M | 651.60M | 585.40M | 667.50M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 693.20M | 653.00M | 651.60M | 585.40M | 667.50M |
| Cost of Revenue | 348.40M | 310.20M | 306.20M | 274.80M | 312.50M |
| Gross Profit | 344.80M | 342.80M | 345.40M | 310.60M | 355.00M |
| SG&A Expenses | 217.40M | 204.20M | 205.00M | 193.50M | 202.90M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 631.80M | 585.00M | 572.00M | 528.50M | 594.90M |
| Operating Income | 61.40M | 68.00M | 79.60M | 56.90M | 72.60M |
| Income Before Tax | 929.20M | -431.10M | 414.00M | 83.40M | -908.90M |
| Income Tax Expenses | 209.20M | -89.20M | 96.20M | 19.40M | -193.10M |
| Earnings from Continuing Operations | 720.00M | -341.90M | 317.80M | 64.00M | -715.80M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 720.00M | -341.90M | 317.80M | 64.00M | -715.80M |
| EBIT | 61.40M | 68.00M | 79.60M | 56.90M | 72.60M |
| EBITDA | 103.90M | 112.20M | 120.20M | 95.00M | 111.80M |
| EPS Basic | 26.69 | -12.70 | 11.67 | 2.29 | -25.57 |
| Normalized Basic EPS | 1.90 | 1.66 | 1.86 | 1.89 | 1.73 |
| EPS Diluted | 26.65 | -12.70 | 11.67 | 2.29 | -25.57 |
| Normalized Diluted EPS | 1.90 | 1.66 | 1.86 | 1.88 | 1.73 |
| Average Basic Shares Outstanding | 26.98M | 26.92M | 27.23M | 27.94M | 28.00M |
| Average Diluted Shares Outstanding | 27.01M | 26.92M | 27.23M | 27.96M | 28.00M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |